OkuloVision

OkuloVision is a preclinical-stage biotechnology company focused on developing gene therapies for the treatment of chronic retinal diseases. The company's lead programs utilize adeno-associated virus (AAV) vectors to deliver genes that promote antioxidant defenses, specifically targeting the NRF2 pathway to protect retinal cells from oxidative stress. Founded on research from the Wilmer Eye Institute at Johns Hopkins University, OkuloVision aims to address high unmet needs in conditions such as retinitis pigmentosa and geographic atrophy. The company is leveraging its proprietary platform to create long-lasting treatments that could potentially halt or slow the progression of vision loss. OkuloVision operates in collaboration with Bluefield Innovations to advance its therapeutic candidates toward clinical evaluation.